Introduction: A Review Worth Reading

A new review published in the Journal of Oral & Facial Pain and Headache (July 2026) pulled together 16 randomized controlled trials of the two most widely studied oral CGRP receptor antagonists, atogepant and rimegepant. That is a useful exercise, because these two drugs get discussed constantly in clinic and online, often with numbers quoted out of context. This review puts the efficacy and safety data side by side in one place.

The short version: atogepant looks particularly strong for migraine prevention, rimegepant offers a well-tolerated option for acute treatment (and a modest preventive effect when taken every other day), and neither showed hepatic or cardiovascular toxicity signals across the trial programs. The most common side effects were constipation and nausea, generally mild to moderate.

How Gepants Work: The CGRP Story

Calcitonin gene-related peptide (CGRP) is a neuropeptide released from trigeminal nerve endings during migraine attacks. It dilates cranial blood vessels, promotes neurogenic inflammation, and sensitizes pain pathways in the trigeminovascular system. CGRP levels rise during attacks, infusing CGRP can trigger attacks in people with migraine, and blocking CGRP signaling reduces both attack frequency and attack severity. Few targets in headache medicine have this much converging evidence behind them.

Gepants are small molecules that sit in the CGRP receptor and block the peptide from binding. This is the same target the injectable anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) go after, but with practical differences: gepants are oral, they clear from the body in hours to days rather than weeks, and the same class can be used for both acute treatment and prevention depending on the drug and schedule.

What the Review Found

According to the review by Gautier and colleagues, the authors searched PubMed, the Cochrane Library, and Web of Science and included 16 randomized controlled trials in adults with migraine: nine evaluating atogepant and seven evaluating rimegepant. Here are the headline numbers.

A placebo-adjusted reduction of 1 to 2.4 monthly migraine days may sound modest on paper. In practice, these are averages across everyone in the trial, including partial responders and non-responders. A meaningful fraction of participants achieve a 50% or greater reduction in monthly migraine days, and the quality-of-life gains (around 10 points on the MSQ-RFR) reflect real functional improvement: fewer missed workdays, fewer cancelled plans, less time lost to attacks.

For context, the review notes rimegepant's preventive effect (-0.8 days/month vs. placebo when dosed every other day) was comparable to what some anti-CGRP monoclonal antibodies achieved in their own trials. That is a fair comparison to raise, though head-to-head trials between gepants and monoclonal antibodies are still lacking.

Atogepant: Built for Prevention

Atogepant (Qulipta in the US, Aquipta in the EU) is a once-daily oral tablet taken whether or not you have an attack that day. It is the gepant with the strongest preventive data, and the review's conclusion that it is "particularly promising for migraine prevention" tracks with the pivotal trials.

In the ADVANCE trial (episodic migraine, 4 to 14 migraine days per month), atogepant 60 mg daily reduced monthly migraine days by 4.2 from a baseline of about 7.8, versus 2.5 with placebo, a placebo-adjusted difference of -1.7 days (95% CI -2.3 to -1.2, p<0.001). The 10 mg and 30 mg doses also beat placebo. In the PROGRESS trial (chronic migraine, 15 or more headache days per month), atogepant 60 mg once daily and 30 mg twice daily both produced clinically relevant reductions, with placebo-adjusted differences of -1.8 and -2.4 monthly migraine days respectively from baselines near 19 days per month.

Rimegepant: One Drug, Two Jobs

Rimegepant (Nurtec ODT in the US, Vydura in the EU) is a 75 mg orally disintegrating tablet that dissolves on the tongue without water, a practical advantage during attacks with nausea or gastroparesis, which are common because of autonomic dysfunction during migraine attacks.

For acute treatment, the pivotal phase 3 trial found a single 75 mg dose made 21% of participants completely pain-free at 2 hours versus 11% with placebo, and 35% free of their most bothersome symptom versus 27%. The review cites pooled acute data showing complete relief at 2 hours in 31-33% of patients versus about 15% with placebo. The absolute numbers are honest: most people are not completely pain-free at 2 hours with any oral acute medication. But pain freedom is a demanding endpoint, and pain relief (moderate or severe pain dropping to mild or none) occurs in a substantially larger share.

For prevention, rimegepant 75 mg every other day reduced monthly migraine days by 4.3 versus 3.5 with placebo (placebo-adjusted -0.8 days, p=0.0099). Smaller than atogepant's effect, but delivered by the same tablet a person may already use acutely, which makes rimegepant unique: it is the only migraine medication with regulatory approval for both acute and preventive treatment.

Dosing and Evidence at a Glance

This table summarizes the regimens covered in the review and the pivotal trials behind them. Evidence grades reflect the strength and consistency of the underlying randomized data.

Evidence key: Strong (RCT) = supported by randomized placebo-controlled trials. Moderate/Supported = consistent data short of definitive trials. Limited = indirect comparisons or expert inference; interpret cautiously.

Safety Profile: What the Trials Showed

The most reassuring finding across the 16 trials is what did not happen. Early CGRP antagonists from the 2000s (telcagepant, notably) were shelved over liver enzyme elevations. Atogepant and rimegepant showed no signal of hepatic toxicity in their trial programs, and no cardiovascular signal either.

Caveats worth stating plainly. Trial populations are screened and generally healthier than clinic populations, and trials of 12 weeks cannot rule out rare or slow-developing problems. Pregnant and breastfeeding individuals were excluded, so gepants are generally avoided in pregnancy pending registry data. Drug interactions matter for both agents: strong CYP3A4 inhibitors and inducers change gepant levels, so medication lists should be reviewed before starting. And a theoretical question the field is still watching: CGRP is a vasodilator with a possible protective role during ischemia, so long-term blockade in people with vascular disease deserves continued study, even without a signal so far.

Where Gepants Fit in Current Treatment

Gepants did not replace the existing toolkit; they added to it. Current consensus guidance (including the American Headache Society's position statements) supports CGRP-targeting therapies as first-line preventive options alongside the established oral preventives, a shift from earlier guidance that reserved them for people who had failed two or more older drugs.

The honest limitation the review flags is access, not pharmacology: in France, where the authors practice, high cost and restricted reimbursement keep gepants out of many hands. The same story plays out in the US with prior authorizations and step therapy. Older preventives (propranolol, topiramate, amitriptyline, candesartan) remain reasonable, evidence-backed, inexpensive options, and for many people they work well.

"The pharmacology here is a real advance: a purpose-built oral migraine drug with placebo-level tolerability in some trials. The bottleneck is no longer the science, it is whether patients can actually get the prescription filled." - Cerebral Torque

Practical Guidance

If you are considering a gepant with your clinician, a few points make the conversation more productive.

Limitations of the Evidence

This is a narrative review, not a formal meta-analysis, so it summarizes trials rather than statistically pooling them, and its literature search ran through July 2024. The 16 included trials were largely industry-funded, which is standard for drug development but worth knowing. Placebo-adjusted effect sizes for prevention are modest on average, and the comparison between rimegepant and monoclonal antibodies is indirect, drawn across different trial populations. Real-world and long-term data, especially beyond 12-week randomized periods, are still accumulating. None of this undermines the core conclusions, but it frames them: gepants are effective and well tolerated in trials, and their exact place relative to monoclonal antibodies and older preventives is still being defined.

Conclusions

Sixteen randomized trials, summarized in one place, tell a consistent story. Atogepant delivers clinically meaningful prevention across episodic and chronic migraine, with quality-of-life gains that show up in daily function. Rimegepant gives roughly one in three people complete pain freedom at 2 hours in pooled acute data and doubles as a modest every-other-day preventive, the only migraine drug approved for both roles. Side effects are mostly constipation and nausea, mild to moderate, with no hepatic or cardiovascular signal so far.

If triptans have failed you, are off the table for cardiovascular reasons, or you are weighing preventive options with your clinician, this class deserves a place in that conversation. Bring your headache diary.